Merck KGaA (FRA:MRK) Given a €127.00 Price Target at Morgan Stanley
Morgan Stanley set a €127.00 ($149.41) price objective on Merck KGaA (FRA:MRK) in a report issued on Monday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
A number of other equities research analysts also recently weighed in on MRK. Nord/LB set a €108.00 ($127.06) target price on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. set a €110.00 ($129.41) target price on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, August 6th. DZ Bank restated a buy rating on shares of Merck KGaA in a research report on Monday, August 10th. Independent Research set a €124.00 ($145.88) target price on Merck KGaA and gave the stock a buy rating in a research report on Friday, August 7th. Finally, Warburg Research set a €108.00 ($127.06) target price on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, August 6th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company’s stock. Merck KGaA currently has a consensus rating of Hold and a consensus target price of €113.69 ($133.76).
Shares of Merck KGaA stock opened at €124.30 ($146.24) on Monday. Merck KGaA has a 52 week low of €76.60 ($90.12) and a 52 week high of €115.00 ($135.29). The business’s fifty day simple moving average is €114.37 and its 200-day simple moving average is €106.30.
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: Capital Gains Distribution
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.